JPH033662B2 - - Google Patents
Info
- Publication number
- JPH033662B2 JPH033662B2 JP12067082A JP12067082A JPH033662B2 JP H033662 B2 JPH033662 B2 JP H033662B2 JP 12067082 A JP12067082 A JP 12067082A JP 12067082 A JP12067082 A JP 12067082A JP H033662 B2 JPH033662 B2 JP H033662B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- benzazosine
- hexahydro
- phenyl
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000004519 manufacturing process Methods 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 31
- -1 tetrahydrofurfuryl Chemical group 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 229910052736 halogen Chemical group 0.000 claims description 9
- 150000002367 halogens Chemical group 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000006332 fluoro benzoyl group Chemical group 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 50
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 238000002844 melting Methods 0.000 description 33
- 230000008018 melting Effects 0.000 description 33
- 238000000921 elemental analysis Methods 0.000 description 32
- 238000005259 measurement Methods 0.000 description 32
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 238000004364 calculation method Methods 0.000 description 24
- 239000013078 crystal Substances 0.000 description 20
- 239000012458 free base Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000000354 decomposition reaction Methods 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000013076 target substance Substances 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000003533 narcotic effect Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 3
- VMRNOSREMVEDTC-UHFFFAOYSA-N [4-(2-chloro-2-oxoethyl)phenyl] acetate Chemical compound CC(=O)OC1=CC=C(CC(Cl)=O)C=C1 VMRNOSREMVEDTC-UHFFFAOYSA-N 0.000 description 3
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 229960000751 nefopam Drugs 0.000 description 3
- UMQUIRYNOVNYPA-UHFFFAOYSA-N 2-(4-chlorophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=C(Cl)C=C1 UMQUIRYNOVNYPA-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- ZQZZLESJXQAATF-UHFFFAOYSA-N [3-(2-chloro-2-oxoethyl)phenyl] acetate Chemical compound CC(=O)OC1=CC=CC(CC(Cl)=O)=C1 ZQZZLESJXQAATF-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- LKEAXACDEKSPTH-UHFFFAOYSA-N (2-bromo-1-nitroethyl)benzene Chemical compound [O-][N+](=O)C(CBr)C1=CC=CC=C1 LKEAXACDEKSPTH-UHFFFAOYSA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- LOYZVRIHVZEDMW-UHFFFAOYSA-N 1-bromo-3-methylbut-2-ene Chemical compound CC(C)=CCBr LOYZVRIHVZEDMW-UHFFFAOYSA-N 0.000 description 1
- GJDABTPRDFGPCR-UHFFFAOYSA-N 2-(2-bromoethyl)oxolane Chemical compound BrCCC1CCCO1 GJDABTPRDFGPCR-UHFFFAOYSA-N 0.000 description 1
- FXFDJSQOCVDXBX-UHFFFAOYSA-N 2-(3-chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane Chemical compound C1=CC(F)=CC=C1C1(CCCCl)OCCO1 FXFDJSQOCVDXBX-UHFFFAOYSA-N 0.000 description 1
- VWVRASTUFJRTHW-UHFFFAOYSA-N 2-[3-(azetidin-3-yloxy)-4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(OC2CNC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VWVRASTUFJRTHW-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- YYLWXDIGYFPUSK-UHFFFAOYSA-N ethyl 4-chloro-4-oxobut-2-enoate Chemical compound CCOC(=O)C=CC(Cl)=O YYLWXDIGYFPUSK-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- LKHJWXFGOOXBSK-UHFFFAOYSA-N inden-5-one Chemical compound O=C1C=CC2=CC=CC2=C1 LKHJWXFGOOXBSK-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は鎮痛剤として有用な2−ベンズアゾシ
ン誘導体及びその製法に係る。
従来のモルヒネ系鎮痛剤は癌痛の如く激烈な痛
みの軽減には必要とされるものの、麻薬性が高い
ために、長期投与や仮令短期投与であつても集中
投与を必要とする場合には適当なものとは云えな
い。蓋し、中毒症を惹起し場合によつては癈人に
至らしめる可能性を有しているからである。鎮痛
作用の強さと麻薬性との間には何等かの相関関係
が存在するようであり、事実従来非麻薬性と称さ
れて来た薬物の内でもその鎮痛作用が強力なもの
には現在では麻薬性の存在が認められているもの
がある。
従つて、現在渇望されている鎮痛剤は麻薬性が
なく、安全域が汎く且つ又作用の緩和なものであ
る。
本発明の目的はこの要望に副う鎮痛剤として有
用な化合物及びその製法を提供することにある。
本発明による化合物は、式
(式中R1は水素又はハロゲン原子を意味し、R2
は水素;低級アルキル基;シクロアルキル、テト
ラヒドロフルフリル又はフルオルベンゾイルにて
置換された低級アルキル基;低級アルケニル基;
アルキル置換低級アルケニル基;フエニルアルキ
ル基;ヒドロキシ、アミノ又はハロゲンにて置換
されたフエニルアルキル基を意味する)にて2−
ベンズアゾシン誘導体又は薬理学的に認容し得る
その塩である。
上記の式()にて示される化合物において、
低級アルキル基としてはメチル等を例示すること
ができ、シクロアルキルとしてはシクロプロピル
等を例示することができ、低級アルケニル基とし
てはアリル基等を例示することができ、ハロゲン
としては弗素等を例示することができる。
式にて示される化合物は文献未記載の新規物
質であつて、本発明方法によれば、式
(式中R1は前記の意味を有する)にて示される
化合物を還元処理すれば、R2が水素である式
の化合物が得られ、この化合物を
(a) 蟻酸及びホルムアルデヒドと反応させれば、
R2がメチルである式の化合物が得られ、
(b) 式R3X(式中Xはハロゲン原子を意味し、R3
は低級アルキル基;シクロアルキル、テトラヒ
ドロフルフリル又はフルオルベンゾイルにて置
換された低級アルキル基;低級アルケニル基;
アルキル置換低級アルケニル基;フエニルアル
キル基;ヒドロキシ、アミノ又はハロゲンにて
置換されたフエニルアルキル基を意味する)に
て示される化合物と反応させれば、R2が低級
アルキル基;シクロアルキル、テトラヒドロフ
ルフリル又はフルオルベンゾイルにて置換され
た低級アルキル基;低級アルケニル基;アルキ
ル置換低級アルケニル基;フエニルアルキル
基;ヒドロキシ、アミノ又はハロゲンにて置換
されたフエニルアルキル基である式の化合物
が得られ、又
(c) 式R4COX(式中Xは前記の意味を有し、R4
はシクロアルキル基;ハロゲン又はアセトキシ
にて置換されたフエニルメチル基を意味する)
にて示される化合物と反応させ且つ反応生成物
を還元処理すればR2がシクロアルキルメチル
基;ハロゲン又はヒドロキシにて置換されたフ
エネチル基である式の化合物
が得られる。
本発明方法の出発物質として使用される式の
化合物も新規物質であつて、9−アリール−6−
オキシイミノ−6,7,8,9−テトラヒドロ−
5H−ベンゾシクロペンテン−5−オンから出発
して下記反応の式に従い合成することができる。
(式中R1は前記の意味を有する)
上記反応に於て出発物質として用いられている
9−アリール−6−オキシイミノ−6,7,8,
9−テトラヒドロ−5H−ベンゾシクロペンテン
−5−オンはベンゾフエノンから出発して下記反
応式に従い合成することができる〔“J.Org.
Chem.”第23巻第344頁(1958年)及び“J.Med.
Chem.”第17巻第1316頁(1974年)参照〕
(式中R1は前記の意味を有する)
次に、参考例、製造例及び薬理試験に関連して
本発明を更に詳細に説明する。
参考例 1
o−(α−フエニル−γ−シアノプロピル)−安
息香酸
NaOH20gの水溶液220mlに、9−フエニル−
6−オキシイミノ−6,7,8,9−テトラヒド
ロ−5H−ベンゾシクロヘプテン−5−オン28.8
g(0.109モル)を懸濁させ、撹拌下に13〜18℃
で塩化トシル48gのC6H6溶液180mlを1.5時間で
添加し、更に室温で2時間撹拌した後に水層を分
取し、C6H6層をNaOH溶液で抽出し、両者を合
併し、10%HClで酸性となし、析出結晶を取
し、エチルエーテルから再結晶すれば、融点111
〜3℃の無色針状晶として所望化合物24.0g
(83.3%)が得られる。
元素分析値:C17H15NO2
計算;C76.96 H5.70 N5.28
実測;C77.01 H5.72 N5.28
IRνKBr naxcm-1:2250(C≡N)
1695(C≡O)
参考例 2
o−〔α−(o−クロルフエニル)−γ−シアノ
プロピル〕−安息香酸
9−(o−クロルフエニル)−6−オキシイミノ
−6,7,8,9−テトラヒドロ−5H−ベンゾ
シクロペンテン−5−オンから出発し、参考例1
に従い合成された。
結晶形態:無色針状晶(エチルエーテルから再結
晶)
融点:162〜4℃
元素分析:C17H14ClNO2
計算;C68.12 H4.71 N4.67
実測;C67.84 H4.64 N4.73
参考例 3
o−〔α−(p−クロルフエニル)−γ−シアノ
プロピル〕−安息香酸
9−(p−クロルフエニル)−6−オキシイミノ
−6,7,8,9−テトラヒドロ−5H−ベンゾ
シクロペンテン−5−オンから出発し、参考例1
に従い合成された。
結晶形態:無色針状晶(酢酸エチル/n−ヘキサ
ンより再結晶)
融点:138〜41℃
元素分析:C17H14ClNO2
計算;C68.12 H4.71 N4.67
実測;C68.08 H4.69 N4.59
参考例 4
2−(α−フエニル−ω−アミノブチル)−安息
香酸
o−(α−フエニル−γ−シアノプロピル)−安
息香酸(参考例1)10.0g(37.7ミリモル)をエ
タノール500mlに溶解させ、水100ml、濃HCl5ml
及びpt−O20.9gを添加し、水素ガスを導入し、
30℃で撹拌しつつ3時間反応させた。触媒を去
し、液を減圧下に濃縮乾涸させた。得たる樹脂
様物をアセトンで結晶化させ取し、メタノー
ル/メチルエチルケトンより再結晶させれば、融
点183〜5℃の無色プリズム晶として所望化合物
の塩酸塩9.51g(82.5%)が得られる。
元素分析:C17H19NO2・HCl
計算;C66.77 H6.59 N4.58
実測;C66.36 H7.36 N4.39
66.71 7.44 4.46
IRνKBr naxcm-1:1705(C=O)
上記塩酸塩3.05g(10ミリモル)を水10mlに加
熱溶解させ、AcONa・3H2O1.4g(10.3ミリモ
ル)の水溶液4mlを添加し、析出結晶を取し、
液を5c.c.に減圧濃縮し、冷後に析出する結晶を
取し、これら結晶を合併し、メタノール/ジメ
チルホルムアミドより再結晶させれば、融点254
〜7℃の無色プリズム晶として遊離塩基が得られ
る。
元素分析:C17H19NO2
計算;C75.81 H7.11 N5.20
実測;C75.93 H7.03 N5.12
IRKBr naxcm-1:3100〜2400(N+)、
1555(C=O)
参考例 5
6−フエニル−1,2,3,4,5,6−ヘキ
サヒドロ−2−ベンズアゾシン−1−オン
o−(α−フエニル−ω−アミノブチル)安息
香酸(参考例4)2.0gと、ダウサム
(Dowtherm)A(商品名)10mlとをN2気流下に
金属浴で240〜50℃において6時間加熱し、冷後
にn−ヘキサン80mlを添加して溶液部と樹脂様部
とに分けた。
溶液部についてはシリカゲルカラム(n−ヘキ
サン)で処理してダウサムを除去した後にCHCl3
留出部を取得し、又樹脂様部に関してはシリカゲ
ルカラムクロマトグラフイー(CHCl3)で精製
し、これらを合併し、溶媒を減圧留去し、エーテ
ル不溶部を採取し、メタノールより再結晶すれ
ば、融点219〜20℃の無色針状晶として所望化合
物485mg(26%)が得られる。
元素分析:C17H17NO
計算;C81.24 H6.82 N5.57
実測;C80.99 H6.91 N5.53
IRνKBr naxcm-1:1630(C=O)、
3310(NH)
参考例 6
6−(p−クロルフエニル)−1,2,3,4,
5,6−ヘキサヒドロ−2−ベンズアゾシン−
1−オン
o−〔α−(p−クロルフエニル)−γ−シアノ
プロピル〕−安息香酸(参考例3)から出発し、
参考例4及び5に記載の方法に従い合成された。
収率:35%
融点:251〜3℃
元素分析:C17H16ClNO
計算;C71.45 H5.64 N4.90
実測;C71.75 H5.66 N4.93
参考例 7
6−(o−クロルフエニル)−1,2,3,4,
5,6−ヘキサヒドロ−2−ベンズアゾシン−
1−オン
o−〔α−(o−クロルフエニル)−γ−シアノ
プロピル〕−安息香酸(参考例2)から出発し、
参考例4及び5に記載の方法に従い合成された。
収率:70%
融点:219.5〜21.5℃
元素分析:C17H16ClNO
計算;C71.45 H5.64 N4.90
実測;C71.74 H5.65 N4.84
製造例 1
6−フエニル−1,2,3,4,5,6−ヘキ
サヒドロ−2−ベンズアゾシン
6−フエニル−1,2,3,4,5,6−ヘキ
サヒドロ−2−ベンズアゾシン−1−オン(参考
例5)500mg(2ミリモル)を無水テトラヒドロ
フラン50mlに溶解させ、氷冷下にLiAlH4500mgを
添加し20時間に亘り還流処理した。得られる油状
物をアルミナカラムクロマトグラフイー
(CH2Cl2)により分離精製した後に塩酸塩とな
し、メタノール/メチルエチルケトンより再結晶
させれば融点275.5〜7℃の無色プリズム晶とし
て目的化合物の塩酸塩478mg(84.2%)が得られ
る。これは常法によに遊離塩基となすことができ
る。
塩酸塩
元素分析:C17H21N・HCl・1/2H2O
計算;C72.20 H7.48 N4.95
実測;C72.49 H7.27 N4.84
NMR(CD3OD)δppm:
7.7〜6.7
9H、m
m>フエニル)
7.50
4.65(3H、ABq、C1−CH2とC6−Hが重量)
3.35〜3.1(2H、m、C3−CH3)
2.5〜1.85(4H、m、C4−CH2及びC5−CH2)
遊離塩基
NMR(CD3Cl)δppm:
7.5〜6.7
(9H、m、
s、フエニル)
7.45
4.95〜4.55(1H、m、C6−CH)
4.16(2H、ABq J=14Hz、C1−CH2)
3.05〜2.7(2H、m、C3−CH2)
2.3〜1.5(4H、m、C4−CH2及びC5−CH2)
製造例 2
6−フエニル−2−メチル−1,2,3,4,
5,6−ヘキサヒドロ−2−ベンズアゾシン
6−フエニル−1,2,3,4,5,6−ヘキ
サヒドロ−2−ベンズアゾシン塩酸塩(製造例
1)1.23g(4ミリモル)から得た遊離塩基と、
90%HCO2H1.08gと、37%HCHO682mgとを撹
拌しつつ90〜100℃に3時間保つた後に(最初の
5分間は発泡が認められる)、反応混合物に水400
mlを添加し、次に濃アンモニア水を添加してアル
カリ性となした。このアルカリ溶液をエーテル抽
出し、水洗し、Na2SO4乾燥し、溶媒を留去し
た。得たる油状物をシリカゲルカラムクロマトグ
ラフイー(エーテル)で分離精製した後に塩酸塩
となす。メタノール/メチルエチルケトンから再
結晶すれば、融点263.3〜4℃(分解)の無色針
状晶として目的物質の塩酸塩1.25g(96.7%)が
得られる。この塩は常法により遊離塩基となすこ
とができる。
塩酸塩
元素分析:C18H21N・CHl
計算;C75.11 H7.70 N4.87
実測;C74.99 H7.71 N4.63
NMR(CD3OD)δppm:
8.0〜7.1
(9H、m、
s、フエニル)
7.66
4.85(3H、ABq、J=15Hz、C1−CH2、C6−
CH)
3.55〜3.3(2H、m、C3−CH2)
3.13(3H、s、N−CH3)
2.5〜1.8(4H、m、C4−CH2、C5−CH2)
誘離塩基
NMR(CDCl5)δppm:
7.6〜6.8
(9H、m、
s、フエニル)
7.56
5.1〜4.7(1H、m、C6−H)
4.01(2H、ABq、J=15Hz、C1−CH2)
2.9〜2.6(2H、m、C3−CH2)
2.46(3H、s、N−CH3)
2.3〜1.3(4H、m、C4−CH2、C5−CH2)
製造例 3
6−フエニル−2−アリル−1,2,3,4,
5,6−ヘキサヒドロ−2−ベンズアゾシン
6−フエニル−1,2,3,4,5,6−ヘキ
サヒドロ−2−ベンズアゾシン(製造例1)1.23
g(4.5ミリモル)と、NaHCO31.134g(13.5ミ
リモル)と、アリルブロミド0.569g(4.7ミリモ
ル)とをジメチルホルムアミド50mlに添加し撹拌
しつつ5時間に亘り還流処理した。冷後に反応混
合物を大量の水で希釈し、エーテル抽出し、水洗
し、エーテル層を3%塩酸で抽出し、塩酸層を濃
アンモニア水でアルカリ性とし、エーテル抽出
し、水洗し、乾燥し、溶媒を留去させた。得たる
油状物をシリカゲルカラムクロマトグラフイー
(エーテル)で分離精製した後に塩酸塩とし、メ
チルエチルケトンより再結晶させれば融点118.5
〜20℃の無色プリズム晶として目的化合物の塩酸
塩1.273g(90.3%)が得られる。この塩は常法
により遊離塩基となすことができる。
塩酸塩
元素分析:C20H23N・HCl
計算;C76.53 H7.71 N4.46
実測;C76.31 H7.61 N4.26
NMR(CD3OD)δppm:
7.9〜6.8
(9H、m、
s、フエニル)
7.59
6.6〜5.6(3H、m、ビニル)
4.82(3H、ABq、J=15Hz、C1−CH2C6−H)
4.2〜3.95(2H、m、アリル−H)
3.5〜3.2(2H、m、C3−CH2)
2.5〜1.8(4H、m、C4−CH2、C5−CH2)
遊離塩基
NMR(CDCl3)δppm:
7.5〜6.7
(9H、m、
s、フエニル)
7.46
6.5〜5.75、
5.5〜5.1(3H、m、ビニル)
4.01(2H、ABq、C1−CH2)
3.3〜3.05(2H、m、アリル−H)
2.9〜2.6(2H、m、C3−CH2)
2.2〜1.7 m、
(4H、C4−CH2、
1.7〜1.3 m、 C5−CH2)
製造例 4
6−フエニル−2−(3−メチル−2−ブテニ
ル)−1,2,3,4,5,6−ヘキサヒドロ
−2−ベンズアゾシン(塩酸塩)
アリルブロミドの代りに3−メチル−2−ブテ
ニルブロミドを用いた以外は製造例3に従い合成
された。
収率:81.7%
融点:201〜3℃(分解)
元素分析:C22H27N・HCl
計算;C77.28 H8.25 N4.10
実測;C77.06 H8.01 N3.84
製造例 5
6−フエニル−2−テトラヒドロフルフリルメ
チル−1,2,3,4,5,6−ヘキサヒドロ
ベンズアゾシン(蓚酸塩)
アリルブロミドの代りにテトラヒドロフルフリ
ルメチルブロミドを用いた以外は製造例3に従い
合成された。
収率:56.7%
融点:185〜7℃
元素分析:C22H27NO・C2H2O4
計算;C70.05 H7.10 N3.40
実測;C69.83 H7.17 N3.13
製造例 6
6−フエニル−2−フエネチル−1,2,3,
4,5,6−ヘキサヒドロ−2−ベンズアゾシ
ン
6−フエニル−1,2,3,4,5,6−ヘキ
サヒドロ−2−ベンズアゾシン(製造例1)の塩
酸塩1.23g(4.5ミリモル)と、トリエチルアミ
ン1.212g(12ミリモル)とをクロロホルム30ml
に溶解させ、氷冷下にフエニルアセチルクロリド
770mg(4.98ミリモル)のCHCl3溶液20mlを30分
間で滴下し、室温で2時間に亘り撹拌した。溶媒
を減圧下に留去させ、残渣に無水テトラヒドロフ
ラン50mlを添加し、氷冷下にLiAlH41.2gを添加
し撹拌しつつ5時間に亘り還流処理した。冷後水
で分解し、エーテル抽出し、水洗し、Na2SO4乾
燥し、溶媒を留去させ、得たる油状物をシリカゲ
ルカラムクロマトグラフイー(エーテル)で分離
精製した後に塩酸塩となした。メタノール/メチ
ルケトンより再結晶させれば、融点210〜3℃
(分解)の無色プリズム晶として目的物質の塩酸
塩1.391g(81.8%)が得られる。この塩は常法
により遊離塩基となすことができる。
塩酸塩
元素分析:C25H27N・HCl
計算;C79.45 H7.47 N3.71
実測;C79.01 H7.49 N3.68
NMR(CD3OD)δppm:
7.6〜6.7
7.32(14H、m、
s、
s、フエニル)
7.36
4.72(2H、q、J=14Hz、C1−H、C6−H)
3.55〜3.1(4H、m、C3−CH2、N−CH2 −C
−フエニル)
2.3〜1.8(4H、m、C4−CH2、C5−CH2)
遊離塩基
NMR(CDCl3)δppm:
7.4〜6.6
7.24(14Hz、m、
s、
s、フエニル)
7.27
4.9〜4.6(1H、m、C6−H)
4.02(2H、ABq、J=14Hz)
4.1〜3.5(2H、m、C1−CH2)
3.0〜2.6(4H、m、C3−CH2、N−CH2 −C−
フエニル)
2.2〜1.0(4H、m、C4−CH2、C5−CH2)
製造例 7
2−フエネチル−6−(o−クロルフエニル)−
1,2,3,4,5,6−ヘキサヒドロ−2−
ベンズアゾシン(塩酸塩)
出発物質として6−(o−クロルフエニル)−
1,2,3,4,5,6−ヘキサヒドロ−2−ベ
ンズアゾシン(製造例16参照)を使用した点以外
は製造例6に従い合成された。
収率:64.5%
融点:245〜50℃(分解)
元素分析:C25H26ClH・HCl
計算;C72.81 H6.60 N3.40
実測;C72.91 H6.70 N3.24
製造例 8
2−(p−ヒドロキシフエネチル)−6−(o−
クロルフエニル)−1,2,3,4,5,6−
ヘキサヒドロ−2−ベンゾアゾシン(塩酸塩)
出発物質として6−(o−クロルフエニル)−
1,2,3,4,5,6−ヘキサヒドロ−2−ベ
ンゾアゾシン(製造例16参照)が使用された点及
びフエニルアセチルクロリドの代りにp−アセト
キシフエニルアセチルクロリドが使用された点を
除き製造例6に従い合成された。
収率:67.7%
融点:290〜5℃(分解)
元素分析:C25H26ClNO・HCl
計算;C70.09 H6.35 N3.27
実測;C69.85 H6.39 N3.01
製造例 9
2−(m−ヒドロキシフエネチル)−6−(o−
クロルフエニル)−1,2,3,4,5,6−
ヘキサヒドロ−2−ベンズアゾシン(塩酸塩)
出発物質として6−(o−クロルフエニル)−
1,2,3,4,5,6−ヘキサヒドロ−2−ベ
ンズアゾシン(製造例16参照)が使用された点及
びフエニルアセチルクロリドの代りにm−アセト
キシフエニルアセチルクロリドが使用された点を
除き、製造例6に従い合成された。
収率:81.5%
融点:262〜70℃(分解)
元素分析:C25H26ClNO・HCl
計算;C70.09 H6.35 N3.27
実測;C70.10 H6.42 N3.11
製造例 10
2−フエネチル−6−(p−クロルフエニル)−
1,2,3,4,5,6−ヘキサヒドロ−2−
ベンズアゾシン(塩酸塩)
出発物質として6−(p−クロルフエニル)−
1,2,3,4,5,6−ヘキサヒドロ−2−ベ
ンズアゾシン(製造例17参照)を使用した点以外
は製造例6に従い合成された。
収率:72%
融点:228〜33℃
元素分析:C25H26ClN・HCl
計算;C72.81 H6.60 N3.40
実測;C73.09 H6.40 N3.39
製造例 11
2−(p−クロルフエネチル)−6−(p−クロ
ルフエニル)−1,2,3,4,5,6−ヘキ
サヒドロ−2−ベンズアゾシン(塩酸塩)
出発物質として6−(p−クロルフエニル)−
1,2,3,4,5,6−ヘキサヒドロ−2−ベ
ンズアゾシン(製造例17参照)が使用された点及
びフエニルアセチルクロリドの代りにp−クロル
フエニルアセチルクロリドが使用された点を除き
製造例6に従い合成された。
収率:57.2%
融点:268〜72℃(分解)
元素分析:C25H25Cl2N・HCl
計算;C67.20 H5.86 N3.13
実測;C67.14 H5.71 N3.16
製造例 12
2−(p−ヒドロキシフエネチル)−6−(p−
クロルフエニル)−1,2,3,4,5,6−
ヘキサヒドロ−2−ベンズアゾシン(塩酸塩)
出発物質として6−(p−クロルフエニル)−
1,2,3,4,5,6−ヘキサヒドロ−2−ベ
ンズアゾシン(製造例17参照)が使用された点及
びフエニルアセチルクロリドの代りにp−アセト
キシフエニルアセチルクロリドが使用された点を
除き製造例6に従い合成された。
収率:57.2%
融点:268〜73℃
元素分析:C25H26ClNO・HOl
計算;C70.09 H6.35 N3.27
実測;C70.14 H6.12 N3.24
製造例 13
2−(m−ヒドロキシフエネチル)−6−(p−
クロルフエニル)−1,2,3,4,5,6−
ヘキサヒドロ−2−ベンズアゾシン(塩酸塩)
出発物質として6−(p−クロルフエニル)−
1,2,3,4,5,6−ヘキサヒドロ−2−ベ
ンズアゾシン(製造例17参照)が使用された点及
びフエニルアセチルクロリドの代りにm−アセト
キシフエニルアセチルクロリドが使用された点を
除き製造例6に従い合成された。
収率:89.5%
融点:245〜51℃
元素分析:C25H26ClNO・HCl
計算;C70.09 H6.35 N3.27
実測;C70.28 H6.49 N3.01
製造例 14
2−(p−クロルフエネチル)−6−フエニル−
1,2,3,4,5,6−ヘキサヒドロ−2−
ベンズアゾシン(塩酸塩)
フエニルアセチルクロリドの代りにp−クロル
フエニルアセチルクロリドが使用された点を除き
製造例6に従い合成された。
収率:91.7%
融点:251〜6℃(分解)
元素分析:C25H26NCl・HCl
計算;C72.81 H6.60 N3.40
実測;C72.73 H6.48 N3.44
製造例 15
2−(p−ヒドロキシフエネチル)−6−フエニ
ル−1,2,3,4,5,6−ヘキサヒドロ−
2−ベンズアゾシン(塩酸塩)
フエニルアセチルクロリドの代りにp−アセト
キシフエニルアセチルクロリドが使用された点を
除き製造例6に従い合成された。
収率:73.3%
融点:226〜9℃(分解)
元素分析:C25H27NO・HCl
計算;C76.22 H7.16 N3.56
実測;C76.50 H7.12 N3.57
製造例 16
2−シクロプロピルメチル−6−フエニル−
1,2,3,4,5,6−ヘキサヒドロ−2−
ベンズアゾシン(塩酸塩)
フエニルアセチルクロリドの代りにシクロプロ
パンカルボニルクロリドが使用された点を除き製
造例6に従い合成された。
収率:83.1%
融点:195〜7℃
元素分析:C21H25N・HCl
計算;C76.92 H7.99 N4.27
実測;C76.76 H8.11 N4.06
参考例 8
o−〔α−(o−クロルフエニル)−ω−アミノ
ブチル〕−安息香酸
o−〔α−(クロルフエニル)−γ−シアノプロ
ピル〕−安息香酸1g(3.34ミリモル)を酢酸140
mlに溶解させ、濃HCl16.7mlとPt−C100mgとを添
加し、水素気流下に室温で7時間に亘り撹拌し
た。
触媒を別し、液を減圧濃縮し、得たる残渣
をエタノール水溶液に溶解させ、酢酸ナトリウム
溶液にて中和すれば所望化合物750mg(74%)が
得られる。エタノールから再結晶させれば融点
270〜2℃(分解)の無色プリズム晶となる。
元素分析:C17H18ClNO2・1/2H2O
計算;C65.27 H6.12 N4.48
実測;C65.31 H6.02 N4.23
IRνKBr naxcm-1:1530(C=O)
MS(m/e):303(M+)
この化合物は参考例5記載の方法に準じて処理
することにより6−(o−クロルフエニル)−1,
2,3,4,5,6−ヘキサヒドロ−2−ベンズ
アゾシン−1−オンに変ずることができる。
参考例 9
o−〔α−(p−クロルフエニル)−ω−アミノ
ブチル〕−安息香酸
o−〔α−(p−クロルフエニル)−γ−アミノ
プロピル〕−安息香酸より出発し参考例8に従い
合成された。
収率:81.5%
融点:267〜71℃(分解)
元素分析:C17H18ClNO2
計算;C67.19 H5.97 N4.61
実測;C67.28 H6.08 N4.65
この化合物は参考例5記載の方法に準じて処理
することにより6−(o−クロルフエニル)−1,
2,3,4,5,6−ヘキサヒドロ−2−ベンズ
アゾシン−1−オンに変ずることができる。
製造例 17
6−(o−クロルフエニル)−1,2,3,4,
5,6−ヘキサヒドロ−2−ベンズアゾシン
6−(o−クロルフエニル)−1,2,3,4,
5,6−ヘキサヒドロ−2−ベンズアゾシン−1
−オン(参考例8参照)1g(3.50ミリモル)を
テトラヒドロフラン35mlに添加し氷冷下に
NaBH41g(26.4ミリモル)を添加し、次いで
BF3−エチルエーテル1.7ml(13.5ミリモル)を15
分間で添加し、氷冷下で更に15分間撹拌し、室温
となして30分間撹拌し、その後2時間に亘り還流
処理した。
反応混合物を氷水300ml中に徐々に注入し、
CHCl3抽出し、CHCl3層を分離水洗し、Na2SO4
乾燥し、乾燥剤を別し、液よりCHCl3を留去
し、得たる残渣をシリカゲルカラムクロマトグラ
フイー(CHCl3〜CHCl3/エタノール=1/1)
で分離精製し、Rf=0.9(酢酸エチル/エタノール
=1/1)の未知物質915mgとRf=0.1(エタノー
ル/CHCl3=1/1)の目的物質130mgとを得た。
未知物質分をN2気流下に200〜230℃で45分間
加熱し、短カラムシリカゲルカラムクロマトグラ
フイー(エタノール/CHCl3=1/1)を通した
処、Rf=0.1の目的物質670mgが更に得られた。
上記目的物質を合併し、塩酸塩となし、メチル
エチルケトンから結晶化すれば、目的物質の塩酸
塩800mg(74.2%)が得られる。この塩は常法に
より遊離塩基に変ずることができる。
塩酸塩
結晶形態:無色プリズム晶
融点:216〜20℃
元素分析:C17H18ClN・HCl
計算;C66.24 H6.21 N4.54
実測;C66.49 H6.22 N4.42
IRνKBr naxcm-1:2600(M+)
遊離塩基
MS(CI−NH3、m/q):272(M+1)+
NMR(CDCl3)δppm:
7.7〜6.2(8H、m、Ar−H)
5.2〜4.6(1H、m、C6−H)
4.1(2H、ABq、J=14.0Hz、Δν=24.2Hz、C1
−H2)
3.2〜2.7(2H、m、C3−H2)
2.4〜0.7(4H、m、C4−H2、C5−H2)
2.03(1H、s、NH)
製造例 18
6−(p−クロルフエニル)−1,2,3,4,
5,6−ヘキサヒドロ−2−ベンズアゾシン
(塩酸塩)
6−(p−クロルフエニル)−1,2,3,4,
5,6−ヘキサヒドロ−2−ベンズアゾシン−1
−オン(参考例9参照)から出発して、製造例17
に従い合成された。
収率:76.9%
融点:300〜5℃(分解)
元素分析:C17H18ClN・HCl
計算;C66.24 H6.21 N4.54
実測;C65.81 H6.13 N4.49
製造例 19
2−(p−アミノフエネチル)−6−(p−クロ
ルフエニル)−1,2,3,4,5,6−ヘキ
サヒドロ−2−ベンズアゾシン
6−(p−クロルフエニル)−1,2,3,4,
5,6−ヘキサヒドロ−2−ベンズアゾシン塩酸
塩(製造例18)3.08g(10.0ミリモル)と、p−
ニトロフエネチルブロミド3.45g(15.0ミリモ
ル)と、NaHCO32.52g(30.0ミリモル)と、ジ
メチルホルムアミド50mlとの混合物を100〜105℃
で15時間に亘り撹拌した。反応混合物を水200ml
に投入し、エチルエーテル抽出し(4回)、水洗
し、Na2SO4乾燥し、減圧濃縮すれば黄褐色油状
物4.5gが得られる。
この油状物を短シリカゲルカラムクロマトグラ
フイー(エチルエーテル/n−ヘキサン=1/
1)にて分離精製し塩酸塩とし、メタノール/メ
チルエチルケトンから再結晶すれば、融点245〜
8℃(分解)の無色プリズム晶として2−(p−
ニトロフエネチル)−6−(p−クロルフエニル)
−1,2,3,4,5,6−ヘキサヒドロ−2−
ベンズアゾシンの塩酸塩3.32g(70.6%)が得ら
れる。
この塩2.50g(5.48ミリモル)をジメチルホル
ムアミド50mlに溶解させ、5%Pd−C300mgを添
加し、水素気流下に室温で7時間に亘り撹拌し
た。
反応混合物を水200ml中に投入し、NH3水でア
ルカリ性となし、エチルエーテルにて希釈した後
に触媒を別し、エチルエーテル抽出し(4回)、
水洗し、Na2SO乾燥し、減圧濃縮すれば黄色油
状物2.3gが得られる。この油状物をシリカゲル
カラムクロマトグラフイー(シリカゲル100g、
トリエチルアミン/酢酸エチル/n−ヘキサン=
1/1/10〜1/2/10)で分離精製すれば、融
点258〜63℃(分解)の無色プリズム晶として目
的物質の塩酸塩1.68g(66%)が得られる。この
塩は常法により遊離塩基に変ずることができる。
塩酸塩
元素分析:C25H27ClN2・2HCl
計算;C64.73 H6.30 N6.04
実測;C64.18 H6.29 N5.76
IRνKBr naxcm- 1:2780(NH3 +)、
2580(NH+)
遊離塩基
IRνKBr naxcm-1:3360(NH2)
NMR(CDCl3)δppm:
7.5〜6.5(12H、m、Ar−H)
5.0〜4.6(1H、m、C6−H)
4.02(2H、ABq、J=14.0Hz、Δν=22Hz、C1−
H)
3.40(2H、幅広s、NH2)
3.0〜2.5(6H、m、C3−H及びNCH2 CH2 Ar)
2.4〜1.2(4H、m、−CH2−)
製造例 20
2−(p−アミノフエネチル)−6−フエニル−
1,2,3,4,5,6−ヘキサヒドロ−2−
ベンズアゾシン(塩酸塩)
6−フエニル−1,2,3,4,5,6−ヘキ
サヒドロ−2−ベンズアゾシン(製造例1)から
出発した以外は製造例19と同様にして合成され
た。
収率:52.1%
融点:283〜7℃(分解)
元素分析:C25H28N2・2HCl・1/2H2O
計算;C68.48 H7.13 N6.39
実測;C68.20 H7.09 N6.12
製造例 21
E−エチル−4〔〔4−〔2−(1,2,3,4,
5,6−ヘキサヒドロ−6−フエニル−2−ベ
ンズアゾシン−2−イル)エチル〕フエニルア
ミノ〕−4−オキソ−2−ブテノアート
アルゴン気流下に2−(p−アミノフエネチル)
−1,2,3,4,5,6−ヘキサヒドロ−6−
フエニル−2−ベンズアゾシン(製造例20)1.60
g(4.49ミリモル)をテトラヒドロフラン70ml中
に溶解させ、0℃でエチル−3−(クロルホルミ
ル)アクリラート803mg(4.94ミリモル)のテト
ラヒドロフラン溶液を45分間で添加し、更に30分
間に亘り撹拌した。
析出結晶を取し、NH3水でアルカリ性とな
し、CH2Cl2抽出し、水洗し、Na2SO4乾燥し、減
圧濃縮し、短シリカゲルカラムクロマトグラフイ
ー(エチルエーテル)すれば、黄色油状物2.06g
(95.2%)得られる。メタノール中で塩酸塩とな
し、メタノール/メチルエチルケトンから再結晶
すれば融点183〜5℃(分解)の無色プリズム晶
として目的物質の塩酸塩が得られる。この塩は常
法により遊離塩基となすことができる。
塩酸塩
元素分析:C31H34N2O3・HCl・1/2H2O
計算;C70.50 H6.87、N5.30
実測;C70.46 H6.70 N5.32
IRνKBr naxcm-1:2580(NH+)、1710、
1670(C=O)
遊離塩基
NMR(CDCl3)δppm:
8.0〜7.7(1H、m、H
NC=O
、D2O添加で消失)
7.7〜6.5(15H、m、オレフイン性プロトン及び
Ar−H)
5.0〜4.6(1H、m、C6−H)
4.25(2H、q、J=7.0Hz、−CH2 CH3)
4.00(2H、ABq、J=14.0Hz、Δν=22.0Hz、C1
−H2)
3.1〜2.5(6H、m、C3−H2、NCH2CH2Ar)
2.5〜1.4(4H、m、−CH2−)
1.31(3H、t、J=7.0Hz、−CH2CH3 )
MS:
EIm/z;482(M+)、250(塩基)、
CI(i−Bu)m/z:483(M+1)
ハイMSm/z:C31H34N2O3(M+)
計算;482、2569
実測;482、2571
製造例 22
2−〔3−(4−フルオルベンゾイル)プロピ
ル〕−1,2,3,4,5,6−ヘキサヒドロ
−6−フエニル−2−ベンズアゾシン
アルゴン気流下に、6−フエニル−1,2,
3,4,5,6−ヘキサヒドロ−2−ベンズアゾ
シン(製造例1)1.78g(7.50ミリモル)と、2
−(3−クロルプロピル)−2−(4−フルオルフ
エニル)−1,3−ジオキソラン2.20g(9.0ミリ
モル)と、NaHCO3945mg(11.3ミリモル)と、
ジメチルホルムアミド30mlとの混合物を100℃で
6時間に亘り撹拌した。
反応混合物にH2O200mlを添加し、エチルエー
テル抽出し、水洗し、Na2SO4乾燥し、減圧濃縮
し、カラムクロマトグラフイー(シリカゲル120
g、エチルエーテル/CH2Cl2/1/3〜エチル
エーテル)で分離精製し、Rf=0.6(シリカゲル、
酢酸エチル)の目的化合物2.57g(77.0%)を得
た。
これをメタノール50mlに溶解させ、3N−HCl6
mlを添加し、室温で2時間撹拌し、減圧濃縮し、
メタノール/メチルエチルケトンから結晶化すれ
ば目的物質の塩酸塩2.14g(65.2%)が得られ
る。これをエタノールから再結晶させれば、融点
220〜222℃(分解)の無色プリズム晶となる。
この塩は常法により遊離塩基となすことができ
る。
塩酸塩
元素分析:C27H28FNO・HCl
計算;C74.04 H6.67 N3.20
実測;C73.85 H6.68 N3.18
IRνKBr naxcm-1:2550(NH+)、1685(C=O)
遊離塩基
NMR(CDCl3)δppm:
8.2〜7.8(2H、m、C2、C6−H)
7.5〜6.5(13H、m、Ar−H)
5.0〜4.6(1H、m、C6−H)
3.92(2H、ABq、J=14.0Hz、Δν=24.0Hz、C1
−H2)
3.3〜1.2(12H、m、−CH2)−
MS:
EIm/z:401(M+)、250(塩基)
CI(i−Bu)m/z:402(M+1)
ハイMSm/z:C27H28FNO(M+)
計算;401、2155
実測;401、2156
薬理試験
dd系雌性マウスを実験動物とし、本発明によ
る化合物の内で代表的なもの及び非麻薬性鎮痛剤
と称されている公知のネフオパムを被験物質と
し、鎮痛効果(抑制率をハフナー法及び酢酸スト
レツチング法で測定し、又急性毒性を測定した結
果は次表に示される通りであつた。
この表から、本発明による化合物がネフオパム
と比較してその作用が略々同様であり、安全域に
於てネフオパムよりも優れているものがあること
が判る。
The present invention relates to a 2-benzazosine derivative useful as an analgesic and a method for producing the same. Conventional morphine-based analgesics are needed to alleviate severe pain such as cancer pain, but due to their high narcotic properties, they cannot be used in cases where intensive administration is required, even for long-term or short-term administration. I can't say it's appropriate. This is because it has the potential to cause toxicosis and, in some cases, lead to epilepsy. There seems to be some kind of correlation between the strength of analgesic effect and narcotic properties, and in fact, even among drugs that were traditionally called non-narcotic, those with strong analgesic effects are now Some substances are recognized to have narcotic properties. Therefore, the currently desired analgesics are non-narcotic, have a wide safety margin, and have mild effects. The purpose of the present invention is to meet this need by providing a compound useful as a side-effect analgesic and a method for producing the same. Compounds according to the invention have the formula (In the formula, R 1 means hydrogen or halogen atom, R 2
is hydrogen; lower alkyl group; lower alkyl group substituted with cycloalkyl, tetrahydrofurfuryl or fluorobenzoyl; lower alkenyl group;
Alkyl-substituted lower alkenyl group; phenyl alkyl group; meaning a phenyl alkyl group substituted with hydroxy, amino or halogen), 2-
A benzazosine derivative or a pharmacologically acceptable salt thereof. In the compound represented by the above formula (),
Examples of lower alkyl groups include methyl, cycloalkyl includes cyclopropyl, lower alkenyl groups include allyl, and halogen includes fluorine. can do. The compound represented by the formula is a new substance that has not been described in any literature, and according to the method of the present invention, the compound represented by the formula If the compound represented by (in the formula R 1 has the above-mentioned meaning) is subjected to reduction treatment, a compound of the formula in which R 2 is hydrogen will be obtained, and if this compound is reacted with (a) formic acid and formaldehyde, ,
A compound of the formula R 3 X (wherein X means a halogen atom and R 3
is a lower alkyl group; a lower alkyl group substituted with cycloalkyl, tetrahydrofurfuryl or fluorobenzoyl; a lower alkenyl group;
When reacted with a compound represented by an alkyl-substituted lower alkenyl group; a phenylalkyl group; a phenylalkyl group substituted with hydroxy, amino or halogen), R 2 is a lower alkyl group; a cycloalkyl group; A compound of the formula which is a lower alkyl group substituted with tetrahydrofurfuryl or fluorobenzoyl; a lower alkenyl group; an alkyl-substituted lower alkenyl group; a phenyl alkyl group; a phenyl alkyl group substituted with hydroxy, amino or halogen; is obtained, and (c) formula R 4 COX (wherein X has the above meaning, R 4
means a cycloalkyl group; a phenylmethyl group substituted with halogen or acetoxy)
By reacting with the compound shown in and reducing the reaction product, a compound of the formula in which R 2 is a cycloalkylmethyl group; a phenethyl group substituted with halogen or hydroxy can be obtained. The compound of formula used as starting material for the process of the invention is also a new substance, 9-aryl-6-
Oximino-6,7,8,9-tetrahydro-
It can be synthesized starting from 5H-benzocyclopenten-5-one according to the reaction formula below. (In the formula, R 1 has the above-mentioned meaning) 9-aryl-6-oximino-6,7,8, used as a starting material in the above reaction
9-Tetrahydro-5H-benzocyclopenten-5-one can be synthesized starting from benzophenone according to the following reaction formula [“J.Org.
Chem.” Vol. 23, p. 344 (1958) and “J.Med.
Chem.” Vol. 17, p. 1316 (1974)] (In the formula, R 1 has the above-mentioned meaning.) Next, the present invention will be explained in more detail in connection with reference examples, production examples, and pharmacological tests. Reference example 1 o-(α-phenyl-γ-cyanopropyl)-benzoic acid Into 220 ml of an aqueous solution of 20 g of NaOH, 9-phenyl-
6-oximino-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-one 28.8
g (0.109 mol) was suspended at 13-18℃ under stirring.
180 ml of a C 6 H 6 solution containing 48 g of tosyl chloride was added over 1.5 hours, and after further stirring at room temperature for 2 hours, the aqueous layer was separated, the C 6 H 6 layer was extracted with a NaOH solution, and the two were combined. If acidified with 10% HCl, the precipitated crystals were collected, and recrystallized from ethyl ether, the melting point was 111.
24.0 g of desired compound as colorless needles at ~3°C
(83.3%) is obtained. Elemental analysis value: C 17 H 15 NO 2 Calculated; C76.96 H5.70 N5.28 Actual measurement; C77.01 H5.72 N5.28 IRν KBr nax cm -1 : 2250 (C≡N) 1695 (C≡O ) Reference Example 2 o-[α-(o-chlorophenyl)-γ-cyanopropyl]-benzoic acid 9-(o-chlorophenyl)-6-oximino-6,7,8,9-tetrahydro-5H-benzocyclopentene- Starting from 5-on, Reference Example 1
Synthesized according to Crystal form: Colorless needles (recrystallized from ethyl ether) Melting point: 162-4℃ Elemental analysis: C 17 H 14 ClNO 2 Calculated; C68.12 H4.71 N4.67 Measured; C67.84 H4.64 N4. 73 Reference Example 3 o-[α-(p-chlorophenyl)-γ-cyanopropyl]-benzoic acid 9-(p-chlorophenyl)-6-oximino-6,7,8,9-tetrahydro-5H-benzocyclopentene- Starting from 5-on, Reference Example 1
Synthesized according to Crystal form: Colorless needle crystals (recrystallized from ethyl acetate/n-hexane) Melting point: 138-41°C Elemental analysis: C 17 H 14 ClNO 2 calculation; C68.12 H4.71 N4.67 actual measurement; C68.08 H4 .69 N4.59 Reference Example 4 10.0 g (37.7 mmol) of 2-(α-phenyl-ω-aminobutyl)-benzoic acid o-(α-phenyl-γ-cyanopropyl)-benzoic acid (Reference Example 1) Dissolve in 500ml of ethanol, 100ml of water, and 5ml of concentrated HCl.
and 0.9 g of pt-O 2 were added, hydrogen gas was introduced,
The reaction was allowed to proceed for 3 hours while stirring at 30°C. The catalyst was removed and the liquid was concentrated to dryness under reduced pressure. The resulting resin-like substance is crystallized from acetone and recrystallized from methanol/methyl ethyl ketone to obtain 9.51 g (82.5%) of the hydrochloride of the desired compound as colorless prismatic crystals with a melting point of 183-5°C. Elemental analysis: C 17 H 19 NO 2・HCl Calculation: C66.77 H6.59 N4.58 Actual measurement: C66.36 H7.36 N4.39 66.71 7.44 4.46 IRν KBr nax cm -1 : 1705 (C=O) Above Dissolve 3.05 g (10 mmol) of hydrochloride in 10 ml of water by heating, add 4 ml of an aqueous solution of 1.4 g (10.3 mmol) of AcONa.3H 2 O, and collect the precipitated crystals.
Concentrate the liquid under reduced pressure to 5 c.c., collect the crystals that precipitate after cooling, combine these crystals, and recrystallize from methanol/dimethylformamide to obtain a melting point of 254.
The free base is obtained as colorless prismatic crystals at ~7°C. Elemental analysis: C 17 H 19 NO 2 calculation; C75.81 H7.11 N5.20 actual measurement; C75.93 H7.03 N5.12 IR KBr nax cm -1 : 3100-2400 (N + ), 1555 (C= O) Reference example 5 6-phenyl-1,2,3,4,5,6-hexahydro-2-benzazocin-1-one o-(α-phenyl-ω-aminobutyl)benzoic acid (Reference example 4) 2.0 g and 10 ml of Dowtherm A (trade name) were heated at 240 to 50°C for 6 hours in a metal bath under a N 2 stream, and after cooling, 80 ml of n-hexane was added to separate the solution part and resin-like part. Divided into. The solution part was treated with a silica gel column (n-hexane) to remove dowsum, and then CHCl 3
The distillate fraction was obtained, and the resin-like fraction was purified by silica gel column chromatography (CHCl 3 ), these were combined, the solvent was distilled off under reduced pressure, the ether-insoluble fraction was collected, and it was recrystallized from methanol. 485 mg (26%) of the desired compound are obtained as colorless needles with a melting point of 219-20°C. Elemental analysis: C 17 H 17 NO Calculation; C81.24 H6.82 N5.57 Actual measurement; C80.99 H6.91 N5.53 IRν KBr nax cm -1 : 1630 (C=O), 3310 (NH) Reference example 6 6-(p-chlorophenyl)-1,2,3,4,
5,6-hexahydro-2-benzazosine-
Starting from 1-one o-[α-(p-chlorophenyl)-γ-cyanopropyl]-benzoic acid (Reference Example 3),
It was synthesized according to the method described in Reference Examples 4 and 5. Yield: 35% Melting point: 251-3℃ Elemental analysis: C 17 H 16 ClNO Calculated; C71.45 H5.64 N4.90 Measured; C71.75 H5.66 N4.93 Reference example 7 6-(o-chlorophenyl )-1, 2, 3, 4,
5,6-hexahydro-2-benzazosine-
Starting from 1-one o-[α-(o-chlorophenyl)-γ-cyanopropyl]-benzoic acid (Reference Example 2),
It was synthesized according to the method described in Reference Examples 4 and 5. Yield: 70% Melting point: 219.5-21.5℃ Elemental analysis: C 17 H 16 ClNO Calculation; C71.45 H5.64 N4.90 Actual measurement; C71.74 H5.65 N4.84 Production example 1 6-phenyl-1, 2,3,4,5,6-hexahydro-2-benzazosine 6-phenyl-1,2,3,4,5,6-hexahydro-2-benzazosin-1-one (Reference Example 5) 500 mg (2 mmol) was dissolved in 50 ml of anhydrous tetrahydrofuran, 500 mg of LiAlH 4 was added under ice cooling, and the mixture was refluxed for 20 hours. The resulting oil is separated and purified by alumina column chromatography (CH 2 Cl 2 ) to form a hydrochloride, and recrystallized from methanol/methyl ethyl ketone to obtain the hydrochloride of the target compound as colorless prism crystals with a melting point of 275.5-7°C. 478 mg (84.2%) is obtained. This can be made into the free base in conventional manner. Hydrochloride elemental analysis: C 17 H 21 N・HCl・1/2H 2 O Calculation; C72.20 H7.48 N4.95 Actual measurement; C72.49 H7.27 N4.84 NMR (CD 3 OD) δppm: 7.7~ 6.7 9H, m m>phenyl) 7.50 4.65 (3H, ABq, C1 - CH2 and C6 -H are weights) 3.35-3.1 (2H, m, C3 - CH3 ) 2.5-1.85 (4H, m, C4 - CH2 and C5 - CH2 ) Free base NMR ( CD3Cl ) δppm: 7.5-6.7 (9H, m, s, phenyl) 7.45 4.95-4.55 (1H, m, C6 -CH) 4.16 ( 2H, ABq J=14Hz, C1 - CH2 ) 3.05-2.7 (2H, m, C3 - CH2 ) 2.3-1.5 (4H, m, C4 - CH2 and C5 - CH2 ) Production example 2 6-phenyl-2-methyl-1,2,3,4,
5,6-hexahydro-2-benzazosine The free base obtained from 1.23 g (4 mmol) of 6-phenyl-1,2,3,4,5,6-hexahydro-2-benzazosine hydrochloride (Preparation Example 1);
After 1.08 g of 90% HCO 2 H and 682 mg of 37% HCHO were kept at 90-100°C for 3 hours with stirring (foaming was observed for the first 5 minutes), 400 g of water was added to the reaction mixture.
ml and then made alkaline by adding concentrated aqueous ammonia. This alkaline solution was extracted with ether, washed with water, dried over Na 2 SO 4 and the solvent was evaporated. The obtained oil is separated and purified by silica gel column chromatography (ether) and then converted into a hydrochloride. Recrystallization from methanol/methyl ethyl ketone yields 1.25 g (96.7%) of the hydrochloride salt of the target compound as colorless needle crystals with a melting point of 263.3-4°C (decomposition). This salt can be made into the free base by conventional methods. Hydrochloride elemental analysis: C 18 H 21 N・CHl Calculated; C75.11 H7.70 N4.87 Actual measurement; C74.99 H7.71 N4.63 NMR (CD 3 OD) δppm: 8.0-7.1 (9H, m, s, phenyl) 7.66 4.85 (3H, ABq, J=15Hz, C 1 −CH 2 , C 6 −
CH) 3.55-3.3 (2H, m, C3 - CH2 ) 3.13 (3H, s, N- CH3 ) 2.5-1.8 (4H, m, C4 - CH2 , C5 - CH2 ) Dilute base NMR ( CDCl5 ) δppm: 7.6-6.8 (9H, m, s, phenyl) 7.56 5.1-4.7 (1H, m, C6 -H) 4.01 (2H, ABq, J=15Hz, C1 - CH2 ) 2.9 ~2.6 (2H, m, C3 - CH2 ) 2.46 (3H, s, N- CH3 ) 2.3~1.3 (4H, m, C4 - CH2 , C5 - CH2 ) Production example 3 6-phenyl -2-allyl-1,2,3,4,
5,6-hexahydro-2-benzazosine 6-phenyl-1,2,3,4,5,6-hexahydro-2-benzazosine (Production Example 1) 1.23
(4.5 mmol), 1.134 g (13.5 mmol) of NaHCO 3 and 0.569 g (4.7 mmol) of allyl bromide were added to 50 ml of dimethylformamide and refluxed for 5 hours with stirring. After cooling, the reaction mixture was diluted with a large amount of water, extracted with ether, washed with water, the ether layer was extracted with 3% hydrochloric acid, the hydrochloric acid layer was made alkaline with concentrated aqueous ammonia, extracted with ether, washed with water, dried, and the solvent was distilled off. The resulting oil is separated and purified by silica gel column chromatography (ether), converted into a hydrochloride salt, and recrystallized from methyl ethyl ketone to give a melting point of 118.5.
1.273 g (90.3%) of the hydrochloride of the target compound is obtained as colorless prismatic crystals at ~20°C. This salt can be made into the free base by conventional methods. Hydrochloride elemental analysis: C 20 H 23 N・HCl calculation; C76.53 H7.71 N4.46 actual measurement; C76.31 H7.61 N4.26 NMR (CD 3 OD) δppm: 7.9-6.8 (9H, m, s, phenyl) 7.59 6.6~5.6 (3H, m, vinyl) 4.82 (3H, ABq, J=15Hz, C1 - CH2C6 -H) 4.2~3.95 (2H, m, allyl-H) 3.5~3.2 (2H, m, C3 - CH2 ) 2.5-1.8 (4H, m, C4 - CH2 , C5 - CH2 ) Free base NMR ( CDCl3 ) δppm: 7.5-6.7 (9H, m, s, phenyl) 7.46 6.5~5.75, 5.5~5.1 (3H, m, vinyl) 4.01 (2H, ABq, C1 - CH2 ) 3.3~3.05 (2H, m, allyl-H) 2.9~2.6 (2H, m, C 3- CH2 ) 2.2-1.7 m, (4H, C4 - CH2 , 1.7-1.3 m, C5 - CH2 ) Production example 4 6-phenyl-2-(3-methyl-2-butenyl)-1 , 2,3,4,5,6-hexahydro-2-benzazosine (hydrochloride) Synthesized according to Production Example 3 except that 3-methyl-2-butenyl bromide was used instead of allyl bromide. Yield: 81.7% Melting point: 201-3℃ (decomposition) Elemental analysis: C 22 H 27 N・HCl Calculation: C77.28 H8.25 N4.10 Actual measurement: C77.06 H8.01 N3.84 Production example 5 6 -Phenyl-2-tetrahydrofurfurylmethyl-1,2,3,4,5,6-hexahydrobenzazosine (oxalate) Following Production Example 3 except that tetrahydrofurfurylmethyl bromide was used instead of allyl bromide. Synthesized. Yield: 56.7% Melting point: 185-7℃ Elemental analysis: C 22 H 27 NO・C 2 H 2 O 4 Calculation: C70.05 H7.10 N3.40 Actual measurement: C69.83 H7.17 N3.13 Production example 6 6-phenyl-2-phenethyl-1,2,3,
4,5,6-hexahydro-2-benzazosine 1.23 g (4.5 mmol) of hydrochloride of 6-phenyl-1,2,3,4,5,6-hexahydro-2-benzazosine (Production Example 1) and 1.212 g of triethylamine. g (12 mmol) and 30 ml of chloroform
Dissolve phenylacetyl chloride under ice cooling.
20 ml of a 770 mg (4.98 mmol) CHCl 3 solution was added dropwise over 30 minutes, and the mixture was stirred at room temperature for 2 hours. The solvent was distilled off under reduced pressure, 50 ml of anhydrous tetrahydrofuran was added to the residue, and 1.2 g of LiAlH 4 was added under ice cooling, followed by reflux treatment for 5 hours with stirring. After cooling, it was decomposed with water, extracted with ether, washed with water, dried with Na 2 SO 4 , the solvent was distilled off, and the resulting oil was separated and purified by silica gel column chromatography (ether), and then converted into a hydrochloride. . If recrystallized from methanol/methyl ketone, melting point is 210-3℃
(Decomposition) yields 1.391 g (81.8%) of hydrochloride of the target substance as colorless prism crystals. This salt can be made into the free base by conventional methods. Hydrochloride elemental analysis: C 25 H 27 N・HCl Calculated; C79.45 H7.47 N3.71 Actual measurement; C79.01 H7.49 N3.68 NMR (CD 3 OD) δppm: 7.6-6.7 7.32 (14H, m , s, s, phenyl) 7.36 4.72 (2H, q, J=14Hz, C1 - H, C6 -H) 3.55-3.1 (4H, m, C3 - CH2 , N- CH2 -C
-Phenyl) 2.3~1.8 (4H, m, C4 - CH2 , C5 - CH2 ) Free base NMR ( CDCl3 ) δppm: 7.4~6.6 7.24 (14Hz, m, s, s, phenyl) 7.27 4.9~ 4.6 (1H, m, C 6 −H) 4.02 (2H, ABq, J=14Hz) 4.1 to 3.5 (2H, m, C 1 −CH 2 ) 3.0 to 2.6 (4H, m, C 3 −CH 2 , N -C H 2 -C-
phenyl) 2.2 to 1.0 (4H, m, C4 - CH2 , C5 - CH2 ) Production example 7 2-phenethyl-6-(o-chlorophenyl)-
1,2,3,4,5,6-hexahydro-2-
Benzazocine (hydrochloride) 6-(o-chlorophenyl)- as starting material
It was synthesized according to Production Example 6 except that 1,2,3,4,5,6-hexahydro-2-benzazosine (see Production Example 16) was used. Yield: 64.5% Melting point: 245-50℃ (decomposition) Elemental analysis: C 25 H 26 ClH・HCl Calculation: C72.81 H6.60 N3.40 Actual measurement: C72.91 H6.70 N3.24 Production example 8 2 -(p-hydroxyphenethyl)-6-(o-
Chlorphenyl)-1,2,3,4,5,6-
Hexahydro-2-benzazocine (hydrochloride) 6-(o-chlorophenyl)- as starting material
Except that 1,2,3,4,5,6-hexahydro-2-benzazosine (see Preparation Example 16) was used and p-acetoxyphenylacetyl chloride was used instead of phenylacetyl chloride. Synthesized according to Production Example 6. Yield: 67.7% Melting point: 290-5℃ (decomposition) Elemental analysis: C 25 H 26 ClNO・HCl Calculation: C70.09 H6.35 N3.27 Actual measurement: C69.85 H6.39 N3.01 Production example 9 2 -(m-hydroxyphenethyl)-6-(o-
Chlorphenyl)-1,2,3,4,5,6-
Hexahydro-2-benzazosine (hydrochloride) 6-(o-chlorophenyl)- as starting material
Except that 1,2,3,4,5,6-hexahydro-2-benzazosine (see Preparation Example 16) was used and m-acetoxyphenylacetyl chloride was used instead of phenylacetyl chloride. , was synthesized according to Preparation Example 6. Yield: 81.5% Melting point: 262-70℃ (decomposition) Elemental analysis: C 25 H 26 ClNO・HCl Calculation: C70.09 H6.35 N3.27 Actual measurement: C70.10 H6.42 N3.11 Production example 10 2 -Phenethyl-6-(p-chlorophenyl)-
1,2,3,4,5,6-hexahydro-2-
Benzazosine (hydrochloride) 6-(p-chlorophenyl)- as starting material
It was synthesized according to Production Example 6 except that 1,2,3,4,5,6-hexahydro-2-benzazosine (see Production Example 17) was used. Yield: 72% Melting point: 228-33℃ Elemental analysis: C 25 H 26 ClN・HCl Calculation: C72.81 H6.60 N3.40 Actual measurement: C73.09 H6.40 N3.39 Production example 11 2-(p -Chlorphenethyl)-6-(p-chlorophenyl)-1,2,3,4,5,6-hexahydro-2-benzazosine (hydrochloride) 6-(p-chlorophenyl)- as starting material
Except that 1,2,3,4,5,6-hexahydro-2-benzazosine (see Preparation Example 17) was used and p-chlorophenylacetyl chloride was used instead of phenylacetyl chloride. Synthesized according to Production Example 6. Yield: 57.2% Melting point: 268-72℃ (decomposition) Elemental analysis: C 25 H 25 Cl 2 N・HCl Calculation: C67.20 H5.86 N3.13 Actual measurement: C67.14 H5.71 N3.16 Production example 12 2-(p-hydroxyphenethyl)-6-(p-
Chlorphenyl)-1,2,3,4,5,6-
Hexahydro-2-benzazosine (hydrochloride) 6-(p-chlorophenyl)- as starting material
Except that 1,2,3,4,5,6-hexahydro-2-benzazosine (see Preparation Example 17) was used and p-acetoxyphenylacetyl chloride was used instead of phenylacetyl chloride. Synthesized according to Production Example 6. Yield: 57.2% Melting point: 268-73℃ Elemental analysis: C 25 H 26 ClNO・HOl Calculation: C70.09 H6.35 N3.27 Actual measurement: C70.14 H6.12 N3.24 Production example 13 2-(m -hydroxyphenethyl)-6-(p-
Chlorphenyl)-1,2,3,4,5,6-
Hexahydro-2-benzazosine (hydrochloride) 6-(p-chlorophenyl)- as starting material
Except that 1,2,3,4,5,6-hexahydro-2-benzazosine (see Preparation Example 17) was used and m-acetoxyphenylacetyl chloride was used instead of phenylacetyl chloride. Synthesized according to Production Example 6. Yield: 89.5% Melting point: 245-51℃ Elemental analysis: C 25 H 26 ClNO・HCl Calculation: C70.09 H6.35 N3.27 Actual measurement: C70.28 H6.49 N3.01 Production example 14 2-(p -chlorphenethyl)-6-phenyl-
1,2,3,4,5,6-hexahydro-2-
Benzazosine (hydrochloride) Synthesized according to Preparation Example 6 except that p-chlorophenylacetyl chloride was used instead of phenylacetyl chloride. Yield: 91.7% Melting point: 251~6℃ (decomposition) Elemental analysis: C 25 H 26 NCl/HCl Calculation: C72.81 H6.60 N3.40 Actual measurement: C72.73 H6.48 N3.44 Production example 15 2 -(p-hydroxyphenethyl)-6-phenyl-1,2,3,4,5,6-hexahydro-
2-Benzazosine (hydrochloride) Synthesized according to Production Example 6 except that p-acetoxyphenylacetyl chloride was used instead of phenylacetyl chloride. Yield: 73.3% Melting point: 226-9℃ (decomposition) Elemental analysis: C 25 H 27 NO・HCl Calculation: C76.22 H7.16 N3.56 Actual measurement: C76.50 H7.12 N3.57 Production example 16 2 -cyclopropylmethyl-6-phenyl-
1,2,3,4,5,6-hexahydro-2-
Benzazosine (hydrochloride) Synthesized according to Preparation Example 6 except that cyclopropanecarbonyl chloride was used in place of phenylacetyl chloride. Yield: 83.1% Melting point: 195-7℃ Elemental analysis: C 21 H 25 N・HCl Calculation: C76.92 H7.99 N4.27 Actual measurement: C76.76 H8.11 N4.06 Reference example 8 o-[α -(o-chlorophenyl)-ω-aminobutyl]-benzoic acid 1 g (3.34 mmol) of o-[α-(chlorphenyl)-γ-cyanopropyl]-benzoic acid was added to 140 ml of acetic acid.
16.7 ml of concentrated HCl and 100 mg of Pt-C were added thereto, and the mixture was stirred at room temperature for 7 hours under a hydrogen stream. The catalyst is separated, the liquid is concentrated under reduced pressure, and the resulting residue is dissolved in an aqueous ethanol solution and neutralized with a sodium acetate solution to obtain 750 mg (74%) of the desired compound. If recrystallized from ethanol, the melting point
It becomes colorless prismatic crystals at 270-2℃ (decomposition). Elemental analysis: C 17 H 18 ClNO 2・1/2H 2 O Calculation; C65.27 H6.12 N4.48 Actual measurement; C65.31 H6.02 N4.23 IRν KBr nax cm -1 : 1530 (C=O) MS (m/e): 303 (M + ) This compound was treated according to the method described in Reference Example 5 to obtain 6-(o-chlorophenyl)-1,
It can be changed to 2,3,4,5,6-hexahydro-2-benzazocin-1-one. Reference Example 9 o-[α-(p-chlorophenyl)-ω-aminobutyl]-benzoic acid Synthesized according to Reference Example 8 starting from o-[α-(p-chlorophenyl)-γ-aminopropyl]-benzoic acid. Ta. Yield: 81.5% Melting point: 267-71℃ (decomposition) Elemental analysis: C 17 H 18 ClNO 2 Calculated; C67.19 H5.97 N4.61 Actual measurement; C67.28 H6.08 N4.65 This compound is a reference example By treating according to the method described in 5, 6-(o-chlorophenyl)-1,
It can be changed to 2,3,4,5,6-hexahydro-2-benzazocin-1-one. Production example 17 6-(o-chlorophenyl)-1,2,3,4,
5,6-hexahydro-2-benzazosine 6-(o-chlorophenyl)-1,2,3,4,
5,6-hexahydro-2-benzazosine-1
Add 1 g (3.50 mmol) of -one (see Reference Example 8) to 35 ml of tetrahydrofuran and cool on ice.
Add 1 g (26.4 mmol) of NaBH 4 and then
BF 3 - 1.7 ml (13.5 mmol) of ethyl ether 15
The mixture was added within 1 minute, stirred for an additional 15 minutes under ice cooling, allowed to reach room temperature, stirred for 30 minutes, and then refluxed for 2 hours. The reaction mixture was slowly poured into 300 ml of ice water,
Extracted with CHCl3 , separated the CHCl3 layer, washed with water, and extracted with Na2SO4 .
After drying and separating the desiccant, CHCl 3 was distilled off from the liquid, and the resulting residue was subjected to silica gel column chromatography (CHCl 3 - CHCl 3 /ethanol = 1/1).
915 mg of an unknown substance with R f =0.9 (ethyl acetate/ethanol = 1/1) and 130 mg of the target substance with R f =0.1 (ethanol/CHCl 3 = 1/1) were obtained. The unknown substance was heated at 200 to 230°C for 45 minutes under a N 2 stream and passed through short column silica gel column chromatography (ethanol/CHCl 3 = 1/1), yielding 670 mg of the target substance with R f = 0.1. More was obtained. By combining the above target substances to form a hydrochloride and crystallizing it from methyl ethyl ketone, 800 mg (74.2%) of the hydrochloride of the target substance is obtained. This salt can be converted to the free base by conventional methods. Hydrochloride crystal form: Colorless prism crystal Melting point: 216-20℃ Elemental analysis: C 17 H 18 ClN・HCl Calculation: C66.24 H6.21 N4.54 Actual measurement: C66.49 H6.22 N4.42 IRν KBr nax cm -1 : 2600 (M + ) Free base MS (CI- NH3 , m/q): 272 (M+1) + NMR ( CDCl3 ) δppm: 7.7-6.2 (8H, m, Ar-H) 5.2-4.6 ( 1H, m, C 6 −H) 4.1 (2H, ABq, J=14.0Hz, Δν=24.2Hz, C 1
−H 2 ) 3.2 to 2.7 (2H, m, C 3 −H 2 ) 2.4 to 0.7 (4H, m, C 4 −H 2 , C 5 −H 2 ) 2.03 (1H, s, NH) Production example 18 6 -(p-chlorophenyl)-1,2,3,4,
5,6-hexahydro-2-benzazosine (hydrochloride) 6-(p-chlorophenyl)-1,2,3,4,
5,6-hexahydro-2-benzazosine-1
- Starting from on (see Reference Example 9), Preparation Example 17
Synthesized according to Yield: 76.9% Melting point: 300-5℃ (decomposition) Elemental analysis: C 17 H 18 ClN・HCl Calculation: C66.24 H6.21 N4.54 Actual measurement: C65.81 H6.13 N4.49 Production example 19 2 -(p-aminophenethyl)-6-(p-chlorophenyl)-1,2,3,4,5,6-hexahydro-2-benzazocine 6-(p-chlorophenyl)-1,2,3,4,
3.08 g (10.0 mmol) of 5,6-hexahydro-2-benzazosine hydrochloride (Production Example 18) and p-
A mixture of 3.45 g (15.0 mmol) of nitrophenethyl bromide, 2.52 g (30.0 mmol) of NaHCO 3 and 50 ml of dimethylformamide was heated at 100-105°C.
The mixture was stirred for 15 hours. Add reaction mixture to 200ml of water
After extraction with ethyl ether (4 times), washing with water, drying over Na 2 SO 4 and concentration under reduced pressure, 4.5 g of a tan oil was obtained. This oil was subjected to short silica gel column chromatography (ethyl ether/n-hexane = 1/
If the hydrochloride is separated and purified in 1) and recrystallized from methanol/methyl ethyl ketone, it will have a melting point of 245~
2-(p-
Nitrophenethyl)-6-(p-chlorophenyl)
-1,2,3,4,5,6-hexahydro-2-
3.32 g (70.6%) of benzazosine hydrochloride are obtained. 2.50 g (5.48 mmol) of this salt was dissolved in 50 ml of dimethylformamide, 300 mg of 5% Pd-C was added, and the mixture was stirred at room temperature under a hydrogen stream for 7 hours. The reaction mixture was poured into 200 ml of water, made alkaline with NH 3 water, diluted with ethyl ether, the catalyst was separated, and extracted with ethyl ether (4 times).
Wash with water, dry with Na 2 SO, and concentrate under reduced pressure to obtain 2.3 g of a yellow oil. This oil was subjected to silica gel column chromatography (silica gel 100g,
Triethylamine/ethyl acetate/n-hexane=
1/1/10 to 1/2/10), 1.68 g (66%) of the hydrochloride of the target substance is obtained as colorless prism crystals with a melting point of 258 to 63°C (decomposition). This salt can be converted to the free base by conventional methods. Hydrochloride elemental analysis: C 25 H 27 ClN 2・2HCl Calculated; C64.73 H6.30 N6.04 Actual measurement; C64.18 H6.29 N5.76 IRν KBr nax cm - 1 : 2780 (NH 3 + ), 2580 (NH + ) Free base IRν KBr nax cm -1 : 3360 (NH 2 ) NMR (CDCl 3 ) δppm: 7.5 to 6.5 (12H, m, Ar-H) 5.0 to 4.6 (1H, m, C 6 -H) 4.02 (2H, ABq, J=14.0Hz, Δν=22Hz, C 1 −
H) 3.40 (2H, wide s, NH2 ) 3.0-2.5 (6H , m, C3 -H and NC H2CH2Ar ) 2.4-1.2 (4H, m, -CH2- ) Production example 20 2 -(p-aminophenethyl)-6-phenyl-
1,2,3,4,5,6-hexahydro-2-
Benzazosine (hydrochloride) Synthesized in the same manner as in Production Example 19 except starting from 6-phenyl-1,2,3,4,5,6-hexahydro-2-benzazosine (Production Example 1). Yield: 52.1% Melting point: 283-7℃ (decomposition) Elemental analysis: C25H28N2 ・ 2HCl・1/ 2H2O Calculated; C68.48 H7.13 N6.39 Actual measurement; C68.20 H7.09 N6.12 Production example 21 E-ethyl-4 [[4-[2-(1,2,3,4,
5,6-Hexahydro-6-phenyl-2-benzazocin-2-yl)ethyl]phenylamino]-4-oxo-2-butenoate 2-(p-aminophenethyl) under argon flow
-1,2,3,4,5,6-hexahydro-6-
Phenyl-2-benzazosine (Production Example 20) 1.60
g (4.49 mmol) was dissolved in 70 ml of tetrahydrofuran, and a solution of 803 mg (4.94 mmol) of ethyl-3-(chloroformyl)acrylate in tetrahydrofuran was added over 45 minutes at 0°C, followed by stirring for a further 30 minutes. The precipitated crystals are collected, made alkaline with NH3 water, extracted with CH2Cl2 , washed with water, dried with Na2SO4 , concentrated under reduced pressure, and subjected to short silica gel column chromatography (ethyl ether) to give a yellow oil. 2.06g
(95.2%) obtained. By converting it into a hydrochloride salt in methanol and recrystallizing it from methanol/methyl ethyl ketone, the hydrochloride salt of the target substance is obtained as colorless prismatic crystals with a melting point of 183-5°C (decomposition). This salt can be made into the free base by conventional methods. Hydrochloride elemental analysis: C 31 H 34 N 2 O 3・HCl・1/2H 2 O Calculated; C70.50 H6.87, N5.30 Actual measurement; C70.46 H6.70 N5.32 IRν KBr nax cm -1 : 2580 (NH + ), 1710, 1670 (C=O) Free base NMR (CDCl 3 ) δppm: 8.0 to 7.7 (1H, m, H NC=O, disappeared by addition of D 2 O) 7.7 to 6.5 (15H, m, olefinic proton and
Ar-H) 5.0 to 4.6 (1H, m, C 6 -H) 4.25 (2H, q, J = 7.0Hz, -CH 2 CH 3 ) 4.00 (2H, ABq, J = 14.0Hz, Δν = 22.0Hz , C 1
−H 2 ) 3.1 to 2.5 (6H, m, C 3 −H 2 , NCH 2 CH 2 Ar) 2.5 to 1.4 (4H, m, −CH 2 −) 1.31 (3H, t, J=7.0Hz, −CH 2 C H 3 ) MS: EIm/z; 482 (M + ), 250 (base), CI (i-Bu) m/z: 483 (M+1) High MSm/z: C 31 H 34 N 2 O 3 ( M + ) Calculation; 482, 2569 Actual measurement; 482, 2571 Production example 22 2-[3-(4-fluorobenzoyl)propyl]-1,2,3,4,5,6-hexahydro-6-phenyl-2 -benzazosine 6-phenyl-1,2,
1.78 g (7.50 mmol) of 3,4,5,6-hexahydro-2-benzazosine (Production Example 1), and 2
-(3-chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane 2.20 g (9.0 mmol) and NaHCO 3 945 mg (11.3 mmol),
The mixture with 30 ml of dimethylformamide was stirred at 100° C. for 6 hours. Add 200 ml of H 2 O to the reaction mixture, extract with ethyl ether, wash with water, dry with Na 2 SO 4 , concentrate under reduced pressure, and perform column chromatography (silica gel 120
g, ethyl ether/CH 2 Cl 2 /1/3 to ethyl ether), and R f =0.6 (silica gel,
2.57 g (77.0%) of the target compound (ethyl acetate) was obtained. Dissolve this in 50ml of methanol and add 3N-HCl6
ml, stirred at room temperature for 2 hours, concentrated under reduced pressure,
Crystallization from methanol/methyl ethyl ketone yields 2.14 g (65.2%) of the target substance, hydrochloride. If this is recrystallized from ethanol, the melting point is
It becomes colorless prismatic crystals at 220-222℃ (decomposition). This salt can be made into the free base by conventional methods. Hydrochloride elemental analysis: C 27 H 28 FNO・HCl Calculated; C74.04 H6.67 N3.20 Actual measurement; C73.85 H6.68 N3.18 IRν KBr nax cm -1 : 2550 (NH + ), 1685 (C =O) Free base NMR ( CDCl3 ) δppm: 8.2-7.8 (2H, m, C2 , C6 -H) 7.5-6.5 (13H, m, Ar-H) 5.0-4.6 (1H, m, C6 −H) 3.92 (2H, ABq, J=14.0Hz, Δν=24.0Hz, C 1
-H 2 ) 3.3 to 1.2 (12H, m, -CH 2 ) - MS: EIm/z: 401 (M + ), 250 (base) CI (i-Bu) m/z: 402 (M+1) High MSm/ z: C 27 H 28 FNO (M + ) Calculation: 401, 2155 Actual measurement: 401, 2156 Pharmacological test DD female mice were used as experimental animals, and representative compounds according to the present invention and non-narcotic analgesics were used. The analgesic effect (inhibition rate) was measured using the Hafner method and the acetic acid stretching method, and the acute toxicity was measured using the well-known Nefopam as the test substance. The results are shown in the table below. From this table, It can be seen that the compounds according to the present invention have substantially the same effect as nefopam, and some are superior to nefopam in terms of safety.
【表】【table】
Claims (1)
は水素;低級アルキル基;シクロアルキル、テト
ラヒドロフルフリル又はフルオルベンゾイルにて
置換された低級アルキル基;低級アルケニル基;
アルキル置換低級アルケニル基;フエニルアルキ
ル基;ヒドロキシ、アミノ又はハロゲンにて置換
されたフエニルアルキル基を意味する) にて示される、2−ベンズアゾシン誘導体又は薬
理学的に認容し得るその塩。 2 式 (式中R1は水素又はハロゲン原子を意味する)
にて示される化合物を還元処理し、得たる生成物
を必要に応じ薬理学的に認容し得るその塩に変ず
ることを特徴とする、式 (式中R1は前記の意味を有する) にて示される2−ベンズアゾシン誘導体又は薬理
学的に認容し得るその塩。 3 式 (式中R1は水素又はハロゲン原子を意味する) にて示される化合物を還元処理し、得たる式 (式中R1は前記の意味を有する) にて示される化合物を蟻酸及びホルムアルデヒド
と反応させ、次いで得たる生成物を必要に応じ薬
理学的に認容し得るその塩に変ずることを特徴と
する、式 (式中R1は前記の意味を有する) にて示される2−ベンズアゾシン誘導体又は薬理
学的に認容し得るその塩。 4 式 (式中R1は水素又はハロゲン原子を意味する) にて示される化合物を還元処理し、得たる式 (式中R1は前記の意味を有する) にて示される化合物を式 R3X () (式中Xはハロゲン原子を意味し、R3は低級ア
ルキル基;シクロアルキル、テトラヒドロフルフ
リル又はフルオルベンゾイルにて置換された低級
アルキル基;低級アルケニル基;アルキル置換低
級アルケニル基;フエニルアルキル基;ヒドロキ
シ、アミノ又はハロゲンにて置換されたフエニル
アルキル基を意味する) にて示される化合物と反応させ、次いで得たる生
成物を必要に応じ薬理学的に認容し得るその塩に
変ずることを特徴とする、式 (式中R1及びR3は前記の意味を有する) にて示される2−ベンズアゾシン誘導体又は薬理
学的に認容し得るその塩の製法。 5 式 (式中R1は水素又はハロゲン原子を意味する) にて示される化合物を還元処理し、得たる、式 (式中R1は前記の意味を有する) にて示される化合物を式 R4COX () (式中Xはハロゲン原子を意味し、R4はシクロ
アルキル基;ハロゲン又はアセトキシにて置換さ
れたフエニルメチル基を意味する) にて示される化合物と反応させ、得られる生成物
を、次いで、還元させた後に必要に応じ薬理学的
に認容し得るその塩に変ずることを特徴とする、
式 (式中R1は前記の意味を有し、R5はシクロアル
キルメチル基;ハロゲン又はヒドロキシにて置換
されたフエネチル基を意味する) にて示される2−ベンズアゾシン誘導体又は薬理
学的に認容し得るその塩の製法。[Claims] 1 formula (In the formula, R 1 means hydrogen or halogen atom, R 2
is hydrogen; lower alkyl group; lower alkyl group substituted with cycloalkyl, tetrahydrofurfuryl or fluorobenzoyl; lower alkenyl group;
A 2-benzazosine derivative or a pharmacologically acceptable salt thereof. 2 formulas (In the formula, R 1 means hydrogen or halogen atom)
A compound represented by the formula (wherein R 1 has the above-mentioned meaning) A 2-benzazosine derivative or a pharmacologically acceptable salt thereof. 3 formulas (In the formula, R 1 means hydrogen or a halogen atom.) The formula obtained by reducing the compound represented by (wherein R 1 has the above-mentioned meaning) is reacted with formic acid and formaldehyde, and the resulting product is then optionally converted into a pharmacologically acceptable salt thereof. ,formula (wherein R 1 has the above-mentioned meaning) A 2-benzazosine derivative or a pharmacologically acceptable salt thereof. 4 formula (In the formula, R 1 means hydrogen or a halogen atom.) The formula obtained by reducing the compound represented by (In the formula, R 1 has the above-mentioned meaning.) A compound represented by the formula R 3 A lower alkyl group substituted with olbenzoyl; a lower alkenyl group; an alkyl-substituted lower alkenyl group; a phenyl alkyl group; a phenyl alkyl group substituted with hydroxy, amino or halogen); reacting and then converting the resulting product, if necessary, into a pharmacologically acceptable salt thereof. (wherein R 1 and R 3 have the above-mentioned meanings) A method for producing a 2-benzazosine derivative or a pharmacologically acceptable salt thereof. 5 formula (In the formula, R 1 means a hydrogen or halogen atom) (In the formula, R 1 has the above meaning) A compound represented by the formula R 4 COX () (In the formula, X means a halogen atom, and R 4 is a cycloalkyl group; substituted with halogen or acetoxy phenylmethyl group), and the resulting product is then reduced and optionally converted into a pharmacologically acceptable salt thereof.
formula (In the formula, R 1 has the above-mentioned meaning, R 5 is a cycloalkylmethyl group; means a phenethyl group substituted with halogen or hydroxy) or a pharmacologically acceptable 2-benzazosine derivative represented by How to make that salt.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12067082A JPS5913760A (en) | 1982-07-13 | 1982-07-13 | Novel benzazocine derivative and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12067082A JPS5913760A (en) | 1982-07-13 | 1982-07-13 | Novel benzazocine derivative and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5913760A JPS5913760A (en) | 1984-01-24 |
| JPH033662B2 true JPH033662B2 (en) | 1991-01-21 |
Family
ID=14792011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12067082A Granted JPS5913760A (en) | 1982-07-13 | 1982-07-13 | Novel benzazocine derivative and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5913760A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2558741A1 (en) * | 2004-04-21 | 2005-11-03 | Sosei R&D Ltd. | Benzoxazocines and their therapeutic use as monoamine reuptake inhibitors |
| GB0408864D0 (en) * | 2004-04-21 | 2004-05-26 | Arakis Ltd | Novel benzoxazocines |
-
1982
- 1982-07-13 JP JP12067082A patent/JPS5913760A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5913760A (en) | 1984-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69303569T2 (en) | Arylalkyl (thio) amides with melatonin receptor selectivity and process for their preparation | |
| JPH07110850B2 (en) | Fluoroalkoxybenzylamino derivatives of nitrogen-containing heterocyclic compounds | |
| JPS6012350B2 (en) | Method for producing novel arylpiperidine derivatives | |
| JP5002592B2 (en) | Azinone and diazinon V3 inhibitors for depression and stress disorders | |
| NL8501826A (en) | NEW 1,4-DIHYDROPYRIDINE DERIVATIVES AND THEIR SALTS, METHOD FOR PREPARING THESE DERIVATIVES AND SALTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM. | |
| JPS5817474B2 (en) | Yuukikagoubutsuni Cansurukairiyou | |
| JPH06500076A (en) | Piperidine compounds, their synthesis and methods of use | |
| JP2632877B2 (en) | Substituted 1H-imidazole compounds | |
| JPH0337554B2 (en) | ||
| JPS63165362A (en) | Substituted aminomethyl-5, 6, 7, 8- tetrahydronaphthyloxyacetic acids, intermediates, production thereof and their use in medicine | |
| JPH033662B2 (en) | ||
| JP4147267B2 (en) | 2-Aminobenzenesulfonic acid derivatives and 2-aminobenzenesulfonyl chloride derivatives, their production and use as synthetic intermediates | |
| JPH07291974A (en) | Epi-epibatidine derivative and its preparation | |
| JP2766319B2 (en) | Glycerin derivative | |
| JPH0372623B2 (en) | ||
| JPH07258250A (en) | Ester derivative | |
| JPS63130581A (en) | Production of 2-substituted-1, 4- dihydropyridines | |
| JPS6183163A (en) | Antitumoral | |
| FR2702211A1 (en) | New derivatives of 2-phenoxyethylamine, their preparation and their therapeutic application. | |
| JPS6353984B2 (en) | ||
| JPS5931753A (en) | 3-(ureidocyclohexylamino)-propan-1,2-diol derivative, manufacture and medicine | |
| JPH0357896B2 (en) | ||
| JP2641879B2 (en) | Preparation of optically active hydantoin derivatives | |
| JPH0156067B2 (en) | ||
| JPH0419991B2 (en) |